Collegium Pharmaceutical
NASDAQ: COLLCanton, US · Virginia corporation · 488 employees on LinkedIn · 6 known investors
Find your way into Collegium Pharmaceutical
Collegium Pharmaceutical is a biopharmaceutical company developing a portfolio of medications to treat serious medical conditions. It serves patients living with serious medical conditions and the healthcare professionals caring for them.
Founders & leadership
MH
Michael HeffernaninFounder · Chairman Emeritus
PB
Paul BrannellyinEVP & Chief Financial Officer2015–2021
VK
Vikram KarnaniinPresident and CEOHe began his career as an electrical engineer and management consultant before transitioning to healthcare, where he spent over a decade at Horizon Therapeutics building and scaling its rare disease commercial operations across 13 countries and leading global commercial strategy and medical affairs through Amgen's $28 billion acquisition of the company.
Board
EN
Eran NadavBoard director
JF
John FreundBoard director
PH
DH
David HirschBoard director
PF
Patrick FortuneBoard director
SH
Stephen HoffmanBoard director
GS
Gino SantiniBoard director
GB
Garen BohlinBoard director
Investors · 6
Reported raises · per SEC filings
Form D private placements$92.5M disclosed across 3 rounds · 2012–2018
▶$20MraisedNov 2018 · 1 investors · PharmaceuticalsRule 506(b)
▶$20MraisedNov 2018 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Michael HeffernanDirector
- David HirschDirector
- Garen BohlinDirector
- Shirley KuhlmannExecutive Officer
- Theodore SchroederDirector
- John A FallonDirector
- Alison B. FlemingExecutive Officer
- Gwen MelincoffDirector
- Gino SantiniDirector
- Scott DreyerExecutive Officer
- Joseph CiaffoniExecutive Officer, Director
- John FreundDirector
- Paul BrannellyExecutive Officer
- Offering amount
- $20M
- Amount sold
- $20M
- First sale
- Nov 2018
- Incorporated
- Corporation, Virginia
- Federal exemptions
- 06b
▶$50MraisedMar 2015 · 18 investors · PharmaceuticalsRule 506(b)
▶$50MraisedMar 2015 · 18 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Gino SantiniDirector
- Eran NadavDirector
- John FreundDirector
- Patrick HeronDirector
- Garen BohlinDirector
- David HirschDirector
- Michael HeffernanExecutive Officer, Director
- Paul BrannellyExecutive Officer
- Offering amount
- $50M
- Amount sold
- $50M
- First sale
- Mar 2015
- Incorporated
- Corporation, Virginia
- Federal exemptions
- 06b
▶$22.5MraisedFeb 2012 · 12 investors · PharmaceuticalsRule 506(b)
▶$22.5MraisedFeb 2012 · 12 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- David HirschDirector
- Patrick HeronDirector
- Patrick FortuneDirector
- Michael HeffernanExecutive Officer, Director
- Stephen HoffmanDirector
- Offering amount
- $22.5M
- Amount sold
- $22.5M
- First sale
- Feb 2012
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 3
by search overlapWalgreens595 shared keywordsWalgreens operates a pharmacy and retail health and wellness business, offering prescription services, over-the-counter medications, health products, and photo services to consumers.
Medscape386 shared keywordsMedscape is an online platform providing medical news, clinical information, and continuing education resources to physicians and healthcare professionals globally. The platform offers CME courses, drug and disease information, and patient education across multiple specialties.
RxWiki261 shared keywordsRxWiki is a consumer-facing health information website that publishes news articles and educational content on medical conditions, treatments, and wellness topics such as scoliosis, seasonal affective disorder, the common cold, heart health, and probiotics.
Companies competing with Collegium Pharmaceutical for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 1 SBIR/STTR award
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2014 | $472.8K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Acquisitions · 1
Early investors' stakes continue via these dealsBioDelivery Sciences
BioDelivery Sciences International was a specialty pharmaceutical company developing pain and neurology treatments, including the opioid product BELBUCA and migraine drug Elyxyb.
In the news
Collegium Pharmaceutical Initiates $50 Million Accelerated Share Buyback with Jefferies LLCkalkinemedia.com · Aug 2026
Collegium Pharmaceutical Reports Q2 2026 Results, Completes AZSTARYS Acquisition and Raises Full-Year Guidance | Quiver Quantitativequiverquant.com · Aug 2026Frequently asked questions
- What does Collegium Pharmaceutical do?
- Collegium Pharmaceutical is a biopharmaceutical company developing a portfolio of medications to treat serious medical conditions. It serves patients living with serious medical conditions and the healthcare professionals caring for them.
- Who founded Collegium Pharmaceutical?
- Collegium Pharmaceutical was founded by Michael Heffernan.
- Who are Collegium Pharmaceutical's investors?
- Collegium Pharmaceutical's investors include APERTURE Venture Partners, EcoR1 Capital, Frazier Life Sciences, Longitude Capital, Boston Millennia Partners, RA Capital.
- How much funding has Collegium Pharmaceutical raised?
- Collegium Pharmaceutical has disclosed $92.5M raised across 3 rounds.
- Where is Collegium Pharmaceutical headquartered?
- Collegium Pharmaceutical is headquartered in Canton, US.